TRAF2 and neoplasm: In this respect, two independent groundbreaking studies give strong evidence that tumor cell-expressed TRAF2 antagonizes the efficacy of checkpoint inhibitor therapies by protection against cell death induction by CD8+-derived TNF (29, 30).